REG-Arix Bioscience PLC Unaudited NAV for November 2023

Arix BioscienceAnnouncement

13/12/2023 07:15

============

   Arix Bioscience PLC (ARIX)
   Unaudited NAV for November 2023

   13-Dec-2023 / 07:00 GMT/BST

   ══════════════════════════════════════════════════════════════════════════

                                        

                              Arix Bioscience plc

                                        

                        Unaudited NAV for November 2023

    

   LONDON, 13 December 2023:  Arix Bioscience plc  (“Arix” or the  “Company”)
   (LSE: ARIX), a transatlantic venture capital company focused on  investing
   in breakthrough biotechnology companies, announces the unaudited estimated
   Net Asset Value (“NAV”) of the Company for the date ended 30 November 2023
   as follows:

    

                                NAV Breakdown                             
                                                               Total
       Date        Listed      Unlisted              Other      NAV     NAV
                  Portfolio   Portfolio    Cash    Interests            per
                                                                       share
    30 November
       2023        £54.3m       £66.4m    £105.8m    £2.6m    £229.1m  £1.77

    (unaudited)

    

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 1 @arixbioscience.com

    

   Powerscourt

   Sarah MacLeod, Nick Johnson, Molly Ring

   +44 (0)20 7250 1446

    2 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience plc is a transatlantic venture capital company focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

    

   ══════════════════════════════════════════════════════════════════════════

   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  MSCM
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   291541
   EQS News ID:    1795525


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1795525&application_name=news&site_id=reuters8

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:arix@powerscourt-group.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1795525&site_id=reuters8&application_name=news


============